Business Wire

IL-PRICEFX

14.7.2020 13:32:09 CEST | Business Wire | Press release

Share
Pricefx Raises $65 Million for Global Expansion and Product Innovation in Series C Financing Round Led by the Apax Digital Fund

Pricefx , the global leader in cloud-native pricing software, today announced it has received $65 million in Series C funding, bringing the company’s total raised to date to $130 million. The round was led by funds advised by Apax Digital , the growth equity team of Apax Partners, with participation from existing investor Digital+ Partners . Pricefx will use the new funding to expand and solidify its global market leadership position as the only true SaaS platform in the pricing industry, accelerate product innovation, extend its partner ecosystem, and evaluate strategic acquisitions.

SaaS solutions have faced increased demand since pandemic measures forced companies to rapidly and radically address digital transformation initiatives. Pricing software, in particular, has seen a tremendous surge in interest owing to the strong return on investment, even in downturns. As a result, Pricefx has signed more than a dozen new customer deals since March of this year.

“Pricing is being recognized as a critical competency for global enterprises and Pricefx is leading the way for a SaaS-based approach,” said Marcin Cichon, CEO and co-founder of Pricefx. “This investment from Apax confirms Pricefx’s resilience, ability to grow its customer base, and innovate – even during challenging times. This investment will further power our global commercial strategy and aggressive product innovation, by attracting critical talent, expanding our growing ecosystem of partners, and enabling further potential strategic acquisitions – all in pursuit of our mission to bring pricing solutions to as many companies as we can, as simply and effectively as possible.”

Pricefx provides a suite of cloud-based pricing software tools – from Price Optimization, Management (PO&M) to Configure-Price-Quote (CPQ) – for B2B and B2C enterprises of all sizes. Additionally, the company launched the first “6 weeks to live” activation accelerator with Lightning , delivering industry-leading time-to-value. The company has supported its clients through the COVID-19 crisis with initiatives such as providing access to its Sales Insights solution free of charge. In May, Pricefx acquired French market leader Brennus Analytics , which brought industry-leading AI capabilities in pricing optimization and Pricefx’s Optimized Dynamic Pricing solution was recently named an SAP endorsed app .

“Pricing is one of the most important value creation levers for businesses, and we share Pricefx’s passion for making pricing software easier, faster and more accessible,” said Mark Beith, Partner of Apax Digital. “Companies are abandoning inefficient manual processes, disparate spreadsheets, and sub-optimal prices, and embracing Pricefx’s next-gen software, which dynamically manages, optimizes and updates prices across all channels.”

“We are thrilled to join Marcin and the whole Pricefx family on their mission to democratize pricing software and deliver best-in-class time to value and exceptional return on investment to their customers,” said Daniel O’Keefe, Managing Partner of Apax Digital.

Concurrent with this investment, Beith and O’Keefe will join Pricefx’s supervisory board.

“We are excited and proud to continue supporting the Pricefx team on their global growth journey. Pricefx demonstrates a relentless drive towards product innovation and customer success and we believe that they are well on-track to build the undisputed global category leader in pricing software,” said Axel Krieger, Founding Partner at Digital+ Partners.

Pricefx was recently named a finalist in Ventana’s 13th Annual Digital Innovation Awards . These awards identify the top technologies that have the most striking impact in their respective markets, recognizing pioneering vendors that contribute advancements in technology, drive change and increase value for organizations worldwide. The company has several disruptive innovations coming this year, including a self-service version of its analytics software, industry-specific Accelerator packages, enhanced CPQ functionality, and an AI-enhanced upgraded version of its PriceOptimizer product.

About Apax Digital

The Apax Digital Fund specializes in growth equity and buyout investments in high-growth enterprise software, consumer internet, and technology-enabled services companies worldwide. The Apax Digital team leverages Apax Partners’ deep tech investing expertise, global platform, and specialized operating experts, to enable technology companies and their management teams to accelerate the achievement of their full potential. For further information, please visit: www.apax.com/digital .

Over its more than 40-year history, Apax Partners has raised and advised funds with aggregate commitments of c.$50 billion. These funds provide long-term equity financing to build and strengthen world-class companies. For more information see: www.apax.com .

About Digital+ Partners

Digital+ Partners is a leading technology growth equity investor focused on European and US technology companies with €350 million assets under management. Digital+ aims to support ambitious entrepreneurs build global technology leaders, providing them with strategic advice and long-term financial support to help them define and execute their growth plans. The fund focuses exclusively on B2B technology investments and leverages a deep corporate network to help portfolio companies access new markets and build new partnerships. For more information please visit: www.dplus.partners .

About Pricefx

Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Its innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Pricefx delivers Passion for Pricing. For more information, please visit www.pricefx.com .

###

Notes to Editors:

London-headquartered Apax Partners (www.apax.com ) and Paris-headquartered Apax Partners (www.apax.fr ) had a shared history but are separate, independent private equity firms.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye